Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Work In Process (2021 - 2023)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Work In Process for 3 consecutive years, with $18.3 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Work In Process rose 189.26% year-over-year to $18.3 million, compared with a TTM value of $18.3 million through Dec 2023, up 189.26%, and an annual FY2023 reading of $18.3 million, up 189.26% over the prior year.
  • Work In Process was $18.3 million for Q4 2023 at Kiniksa Pharmaceuticals International, up from $13.4 million in the prior quarter.
  • Across five years, Work In Process topped out at $18.3 million in Q4 2023 and bottomed at $148000.0 in Q1 2022.
  • Average Work In Process over 3 years is $8.3 million, with a median of $6.5 million recorded in 2022.
  • Peak annual rise in Work In Process hit 9033.11% in 2023, while the deepest fall reached 189.26% in 2023.
  • Year by year, Work In Process stood at $4.2 million in 2021, then surged by 50.9% to $6.3 million in 2022, then surged by 189.26% to $18.3 million in 2023.
  • Business Quant data shows Work In Process for KNSA at $18.3 million in Q4 2023, $13.4 million in Q3 2023, and $6.6 million in Q2 2023.